the abcellera biologics ( acc ) company is a new public company that is a new public company and is a publicly - listed company. it is a new public company and its success is a key factor in our success. we believe that the technology stack that we have assembled over the last nine years offers capabilities in the discovery of therapeutic antibodies that are already unmatched in combined metrics of speed, versatility, and diversity. despite our leading position today, we are far from done. over the coming years, we will continue to invest aggressively in building our technology stack to push back the frontiers of what is possible. we aim to create long - term shareholder value by building a large and diversified portfolio of royalty positions in the next generation of antibody-based therapies.